Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of any of five arginine residues that are hotspots for TP53 mutations in human cancers disables TP53 sequence-specific DNA binding (Cho, et al., 1994).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Cho, et al., 1994
In the citing paper
“Gly-245 in the wild type adopts unusual backbone dihedral angles (1), which are not favored when the residue is replaced by serine.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The crystal structure of p53 core domain shows that the epitope of PAb240, located in strand 7, is inaccessible to antibody binding (1), and at least a partly unfolded form is required to expose the epitope.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The guanidinium group of Arg-249 is salt-bridged to the carboxylate group of Glu-171 in L2 and backbone oxygens of Gly-245 and Met-246 (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“suggesting the structure of p53 core domain in solution is similar to that in crystal structure (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Principles of Nucleic Acid Structure
Saenger, W. (1984) · Springer Advanced Texts in Chemistry · doi:10.1007/978-1-4612-5190-3 · Cited by 4,150
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Research works printed but not linked: 2
- SACK, J. S., JOURNAL OF MOLECULAR GRAPHICS 6: 224 (1988).
- TONRUD, D.E., ACTA CRYSTALLOGR A 43: 489 (1987).
Cited by
Items 1,401–1,500 of 2,517
Insights into Selective Activation of p53 DNA Binding by c-Abl
Wei, G., Li, A. G., & Liu, X. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m409522200 · Cited by 23
Analysis ofp53 mutations andHelicobacter pylori infection in human and animal models
Murakami, K., Fujioka, T., Kodama, M., Honda, S., Okimoto, T., Oda, T., Nishizono, A., Sato, R., Kubota, T., Kagawa, J., et al. (2002) · Journal of Gastroenterology · doi:10.1007/bf02990091 · Cited by 23
Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system
Fulda, S., Łoś, M., Friesen, C., & Debatin, K. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980330)76:1<105::aid-ijc17>3.0.co;2-b · Cited by 182
Molecular basis of choroideremia (CHM): Mutations involving the rab escort protein-1 (REP-1) gene
van den Hurk, J., Schwartz, M., van Bokhoven, H., van de Pol, T., Bogerd, L., Pinckers, A., Bleeker-Wagemakers, E., Pawlowitzki, I., Rüther, K., Ropers, H.-H., et al. (1997) · Human Mutation · doi:10.1002/(sici)1098-1004(1997)9:2<110::aid-humu2>3.0.co;2-d · Cited by 173
Chakrani, F., Armand, J., Lenoir, G., Ju, L., Liang, J., May, E., & May, P. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910610307 · Cited by 22
Structure of the NF-κB transcription factor: a holistic interaction with DNA
Kuriyan, J., & Thanos, D. (1995) · Structure · doi:10.1016/s0969-2126(01)00143-5 · Cited by 23
The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer
Lee, J., Shun, C., Wu, M., Chen, Y.-Y., Yang, S., Hung, H.-I., Chen, J., Hsu, H.-H., Huang, P., Kuo, S., et al. (2005) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2005.09.003 · Cited by 22
Keohavong, P., Gao, W., Mady, H. H., Kanbour‐Shakir, A., & Melhem, M. F. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.03.010 · Cited by 23
“Furthermore, six of the ten mutations, including one DCIS mutation (Table 1, patient 4) and 5 ADH mutations (Table 2, patients 4, 6, 7, 8, and 9), occurred in exon 7 at codons located within region IV of the evolutionarily conserved domain of the p53 protein (residues 234–258) [61,62].”
BackgroundComparison of the Human and Worm p53 Structures Suggests a Way for Enhancing Stability
Pan, Y., Ma, B., Levine, A. J., & Nussinov, R. (2006) · Biochemistry · doi:10.1021/bi052242n · Cited by 24
Mutational Analysis of Human Thioredoxin Reductase 1
Ma, X., Hu, J., Lindner, D. J., & Kalvakolanu, D. V. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202286200 · Cited by 22
Atomic force microscopy reveals kinks in the p53 response element DNA
Balagurumoorthy, P., Lindsay, S. M., & Harrington, R. E. (2002) · Biophysical Chemistry · doi:10.1016/s0301-4622(02)00169-2 · Cited by 22
Balourdas, D.-I., Markl, A. M., Krämer, A., Settanni, G., & Joerger, A. C. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-06739-x · Cited by 24
“Restraints on the backbone conformation in this region have been implicated in the impaired DNA-binding capacity of the cancer hotspot mutant G245S [17, 37].”
BackgroundHwang, S. H., Baek, S. H., Lee, M. J., Kook, Y., Bae, S. J., Ahn, S. G., & Jeong, J. (2024) · Cancers · doi:10.3390/cancers16233899 · Cited by 28
p53/p73 Protein Network in Colorectal Cancer and Other Human Malignancies
Horvat, A., Tadijan, A., Vlašić, I., & Slade, N. (2021) · Cancers · doi:10.3390/cancers13122885 · Cited by 22
“The DBD contains four conserved regions [51] and includes the immunoglobulin-like β-sandwich that serves as a scaffold for the structural elements involved in DNA-binding consisting of two large loops, which are held together by a zinc atom through cysteine and histidine ligands, and a loop–sheet–helix motif [52].”
BackgroundAlcohol Consumption and Rectal Tumor Mutations and Epigenetic Changes
Slattery, M. L., Wolff, R. K., Herrick, J. S., et al. (2010) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3181d325db · Cited by 21
“An arginine residue at codon 248 in the L3 loop of the core domain of the gene is thought to play a critical role in DNA binding; an arginine at codon 175 is located in the L2 loop in the vicinity of the zinc binding site; a glycine at codon 245, also in the L3 loop, allows the L3 loop to assume unique conformations.(…”
BackgroundLiang, X., Guo, Y., Figg, W. D., Fojo, A. T., Mueller, M. D., & Yu, J. (2010) · Chemotherapy Research and Practice · doi:10.1155/2011/715469 · Cited by 23
Impact of Cellular Senescence in Aging and Cancer
Provinciali, M., Cardelli, M., Marchegiani, F., & Pierpaoli, E. (2013) · Current Pharmaceutical Design · doi:10.2174/138161213805219739 · Cited by 24
The Molecular Perspective: p53 Tumor Suppressor
Goodsell, D. S. (1999) · Stem Cells · doi:10.1002/stem.170189 · Cited by 21
Upton, B., Chu, Q. D., & Li, B. D. �. (2008) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2008.08.006 · Cited by 25
“Domains II to V are located within the core DNA-binding region.10 The structure of the core DNA-binding domain consists of two large loops and a loopsheet-helix, which together make the interactions with DNA.11 DNA damage induces TP53 to be stable and more abundant in the cell.12 The increase arrests the cell cycle in…”
BackgroundInfluentialGermline TP53 Mutation and Clinical Characteristics of Korean Patients With Li-Fraumeni Syndrome
Park, K., Choi, H.-J., Suh, S., Ki, C., & Kim, J. (2016) · Annals of Laboratory Medicine · doi:10.3343/alm.2016.36.5.463 · Cited by 23
“Mutation group and domain were based on previously reported structural data and the Pfam database, respectively [8, 17].”
MethodWhat is the potential of p53 isoforms as a predictive biomarker in the treatment of cancer?
Hayman, L., Chaudhry, W. R., Ревин, В. В., Zhelev, N., & Bourdon, J. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1563484 · Cited by 22
“Structurally, the DBD consists of ‘two antiparallel β sheets that have four and five β strands,’ [11] which supports three αhelical loops.”
BackgroundMutant p53 regulates LPA signaling through lysophosphatidic acid phosphatase type 6
Chryplewicz, A., Tienda, S. M., Nahotko, D. A., Peters, P., Lengyel, E. R., & Eckert, M. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-41352-5 · Cited by 23
Roles of p53 Family Structure and Function in Non-Canonical Response Element Binding and Activation
Cai, B., Chao, C., Huang, H., Lee, H.-Y., Kannagi, R., & Chen, J.-Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153681 · Cited by 22
“The DNA-binding domains of p53 represent loop–sheet–helix motif regions that make specific base contacts in the major grooves [29], and 10 bp spacer will make the monomer A and C face the same direction as the major groove and monomer B and D face the another direction of the groove opposite to A and C as indicated in…”
BackgroundRegulation of protein function and degradation by heme, heme responsive motifs, and CO
Fleischhacker, A. S., Sarkar, A., Liu, L., & Ragsdale, S. W. (2021) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2021.1961674 · Cited by 23
Lysine120 Interactions with p53 Response Elements can Allosterically Direct p53 Organization
Pan, Y., & Nussinov, R. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000878 · Cited by 23
“The conformation with Arg248 inserted into the DNA minor groove was captured only in one crystal structure [46].”
BackgroundMethodKobayashi, M., Kawachi, H., Takizawa, T., et al. (2006) · Oncology · doi:10.1159/000106448 · Cited by 21
“Arginine in most of these amino acid bases is known to play an important role in DNA binding [”
BackgroundRosiglitazone ameliorates senescence-like phenotypes in a cellular photoaging model
Chen, L., Bi, B., Zeng, J., Zhou, Y., Yang, P. C., Guo, Y., Zhu, J., Yang, Q., Zhu, N., & Liu, T. (2015) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2015.01.007 · Cited by 23
Identification of functional p53‐binding motifs in the mouse wig‐1 promoter
Wilhelm, M., Méndez‐Vidal, C., & Wiman, K. G. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03004-1 · Cited by 21
D’Erchia, A. M., Pesole, G., Tullo, A., Saccone, C., & Sbisà, E. (1999) · Genomics · doi:10.1006/geno.1999.5794 · Cited by 21
Therapeutic targeting of the p53 tumor suppressor gene
Beaudry, G. A. (1996) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(96)80069-3 · Cited by 21
Radioresistance in Oral Squamous Cell Carcinoma With p 53 DNA Contact Mutation
Yamazaki, Y., Chiba, I., Hirai, A., NOTANI, K.-I., Kashiwazaki, H., Tei, K., Totsuka, Y., Iizuka, T., Kohgo, T., & Fukuda, H. (2003) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000091352.60347.f8 · Cited by 21
“7%) had occurred within conserved regions II-V and 10 were located in the L2 loop (codons 163–195), 4 in the L3 loop (codons 236–251), 3 in the loop–sheet–helix (LSH) motif (codons 273–286), and 4 in cysteine at codon 176, which is critical for the three-dimensional structure of the DNA binding surface brought about b…”
BackgroundYoneda, K., Yokoyama, T., Yamamoto, T., Hatabe, T., & Osaki, T. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00291-3 · Cited by 20
p53 mutations in malignant gliomas.
Li, Y., Millikan, R. C., Carozza, S. E., Newman, B. M., Liu, E., Davis, R. P., Miike, R., & Wrensch, M. (1998) · PubMed · Cited by 21
Transcriptional activation of APAF1 by KAISO (ZBTB33) and p53 is attenuated by RelA/p65
Koh, D., An, H., Kim, M., Jeon, B., Choi, S., Hur, S. S., & Hur, M. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2015.07.008 · Cited by 23
Stability of the core domain of p53: insights from computer simulations
Madhumalar, A., Smith, D. J., & Verma, C. S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-s1-s17 · Cited by 23
“2 Å; [20]); the structures of p63 and p73 were modeled based on the homology with the p53 monomer (sequence similarity to p63 and p73 is 77% and 75% respectively while identity is ~60%).”
BackgroundZhao, L., Zhao, X., Wu, X., & Tang, W. (2013) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2013.0103 · Cited by 20
“The majority of p53 mutations are missense mutations, occurring mainly in the DNA binding domain of the protein (Cho et al., 1994).”
BackgroundAll-codon scanning identifies p53 cancer rescue mutations
Baronio, R., Danziger, S. A., Hall, L., Salmon, K. A., Hatfield, G. W., Lathrop, R. H., & Kaiser, P. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq571 · Cited by 20
“The 3D structure of p53 (51) was visualized with Visual Molecular Dynamics (52).”
MethodOncogenomic Approaches in Exploring Gain of Function of Mutant p53
Donzelli, S., Biagioni, F., Fausti, F., Strano, S., Fontemaggi, G., & Blandino, G. (2008) · Current Genomics · doi:10.2174/138920208784340713 · Cited by 20
“it mutant proteins in two major categories [11,12]: a) DNA contact defective (His273, Trp248), that includes those mutants whose mutation impacts on the residues composing the DNA/protein interaction surface; b) defective structure (His175, His179), whose point mutation determines an important conformational alteratio…”
BackgroundStructures and Unimolecular Reactivity of Gas-Phase [Zn(Proline-H)]+ and [Zn(Proline-H)(H2O)]+
Gholami, A., & Fridgen, T. D. (2013) · The Journal of Physical Chemistry B · doi:10.1021/jp404697g · Cited by 20
Mutant p53 promotes cell spreading and migration via ARHGAP44
Xu, J., Jiao, J., Xu, W. D., Ji, L., Jiang, D., Xie, S., Kubra, S., Li, X., Fu, J., Xiao, J., et al. (2017) · Science China Life Sciences · doi:10.1007/s11427-016-9040-8 · Cited by 19
EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer
Pascal, L. E., Wang, Y., Zhong, M., Wang, D., Chakka, A. B., Yang, Z., Li, F., Song, Q., Rigatti, L. H., Chaparala, S., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2018.01.011 · Cited by 24
Nucleosome Crowding in Chromatin Slows the Diffusion but Can Promote Target Search of Proteins
Kanada, R., Terakawa, T., Kenzaki, H., & Takada, S. (2019) · Biophysical Journal · doi:10.1016/j.bpj.2019.05.007 · Cited by 22
Xu, Q., & Dunbrack, R. L. (2019) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2019.03.006 · Cited by 24
Malhotra, L., Goyal, H., Jhuria, S., Dev, K., Kumar, S., Kumar, M., Kaur, P., & Ethayathulla, A. S. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129807 · Cited by 21
Li, Z., Wang, F., Qian, C., Neumann, R. M., Cheville, J. C., Tindall, D. J., & Liu, W. (2006) · Human Mutation · doi:10.1002/humu.9457 · Cited by 21
“Replacement of these conserved amino acids in the DNA binding domain of TP53 may interfere with the binding ability of TP53 to its target genes (Cho, et al., 1994).”
BackgroundSchlichtholz, B. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh256 · Cited by 20
The p53 Gene Family: Control of Cell Proliferation and Developmental Programs
Morgunkova, A. A. (2005) · Biochemistry (Moscow) · doi:10.1007/s10541-005-0210-4 · Cited by 20
Lee, S. Y., Jeon, H., Hwangbo, Y., Jeong, J. Y., Park, J. Y., Lee, E. J., Jin, G., Shin, K. M., Yoo, S. S., Lee, J., et al. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.22077 · Cited by 20
“predicted from the crystal structure of the TP53-DNA complex, described previously [17,18].”
The p53 Tumor Suppressor Pathway and Cancer
Zambetti, G. P. (2005) · Springer eBooks · doi:10.1007/0-387-30127-5 · Cited by 24
“The p53 residues that are key to its interaction with 53BP1, Arg248 and Arg249, are highly conserved in evolution; however, the evolutionary conservation may reflect the importance of these residues for sequence-specific DNA binding (Cho et al., 1994).”
BackgroundInfluentialSelective base excision repair of DNA damage by the non‐base‐flipping DNA glycosylase AlkC
Shi, R., Mullins, E. A., Shen, X., Lay, K. T., Yuen, P. K., David, S. S., Rokas, A., & Eichman, B. F. (2017) · The EMBO Journal · doi:10.15252/embj.201797833 · Cited by 22
“In contrast to the eukaryotic transcription factors, AlkC’s AB-loop does not contact DNA, despite its orientation toward the DNA (Fig EV1).”
BackgroundInfluential(1998) · Pure Amsterdam UMC · doi:10.1002/(sici)1098-1004(1998)12:1 · Cited by 1
Gao, W., Mady, H. H., Melhem, M. F., & Keohavong, P. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20505 · Cited by 21
“We have previously shown that this codon was a hotspot in lung tumors from AC patients [14] where mutation occurrence has been reported to lead to severe contact p53 mutants in the L3 domain [32,33].”
BackgroundProtein Accumulation and Gene Mutation of p53 in Bilateral Breast Cancer
Stenmark-Askmalm, M. (2001) · Acta Oncologica · doi:10.1080/028418601750071064 · Cited by 20
Gallo, O., Chiarelli, I., Bianchi, S. E., et al. (1996) · PubMed · Cited by 20
Types and localisation of p53 gene mutations
Jassem, E., Nikliński, J., Rosell, R., Niklińska, W., Jakóbkiewicz‐Banecka, J., Monzó, M., Chyczewski, L., Kobierska, G., Skokowski, J., Żylicz, M., et al. (2001) · Lung Cancer · doi:10.1016/s0169-5002(01)00344-0 · Cited by 24
“This region (residues 102–292) covers all known ‘hot spots’ (sites of frequent mutations) for non-small cell lung cancer (NSCLC) localized between exons 5 and 8, particularly in the four highly evolutionary conserved domains [3].”
BackgroundInfluentialImpact of human genome sequencing for in silico target discovery
Sanséau, P. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(01)01724-x · Cited by 23
Regulation of p53-dependent transcription
Jõers, A. (2004) · DSpace repository (University of Tartu) · Cited by 220
Identification of p53-target genes in Danio rerio
Mandriani, B., Castellana, S., Rinaldi, C., Manzoni, M., Venuto, S., Rodríguez-Aznar, E., Galcerán, J., Nieto, M. A., Borsani, G., Monti, E., et al. (2016) · Scientific Reports · doi:10.1038/srep32474 · Cited by 30
Structural basis of the p53 DNA binding domain and PUMA complex
Han, C. W., Lee, H. N., Jeong, M. S., Park, M.-J., & Jang, S. B. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.02.049 · Cited by 20
TP53 in Myelodysplastic Syndromes
Jiang, Y., Gao, S., Soubise, B., Douet‐Guilbert, N., Liu, Z., & Troadec, M. (2021) · Cancers · doi:10.3390/cancers13215392 · Cited by 23
“The DBD binds specifically to doublestrand target DNAs and performs cell cycle arrest and tumor suppression function [22].”
BackgroundInfluentialLYRUS: a machine learning model for predicting the pathogenicity of missense variants
Lai, J., Yang, J., Uzun, E. D. G., Rubenstein, B. M., & Sarkar, I. N. (2021) · Bioinformatics Advances · doi:10.1093/bioadv/vbab045 · Cited by 22
“In addition, more than 80% of somatic TP53 mutations in human cancers occur in this region 69,70 .”
BackgroundGu, J., Wang, B., Liu, Y., Zhong, L., Tang, Y., Guo, H., Jiang, T., Wang, L., Li, Y., & Cai, L. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.12.027 · Cited by 20
“To understand how Zn affects the P53 DNA binding domain, structural studies have indicated that a Zn ion is associated with four hot spots: C176, H179, C238 and C242 [41–43].”
BackgroundA Chemical Modulator of p53 Transactivation that Acts as a Radioprotective Agonist
Morita, A., Takahashi, I., Sasatani, M., Aoki, S., Wang, B., Ariyasu, S., Tanaka, K., Yamaguchi, T., Sawa, A., Nishi, Y., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0554 · Cited by 19
“The ZBS is a cysteine-rich zinc finger–like motif that is located in the DNA-binding domain (17, 20).”
BackgroundWang, H., Lu, C., Zhou, T., Zhang, Z., & Zeng, C. (2021) · Public Health Genomics · doi:10.1159/000516598 · Cited by 19
A role of A nabaena sensory rhodopsin transducer ( ASRT ) in photosensory transduction
Kim, S. Y., Yoon, S. R., Han, S., et al. (2014) · Molecular Microbiology · doi:10.1111/mmi.12635 · Cited by 19
“This immunoglobulin-like structural domain is involved in DNA binding in diverse families of proteins, including the p53-like transcription factors (Cho et al., 1994).”
BackgroundFen, C. X., Coomber, D., Lane, D. P., & Ghadessy, F. J. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.099 · Cited by 23
Transgenic mouse with human mutant p53 expression in the prostate epithelium
Elgavish, A., Wood, P. A., Pinkert, C. A., Eltoum, I.-E. A., Cartee, T. V., WILBANKS, J. T., Mentor-Marcel, R. A., Tian, L., & Scroggins, S. E. (2004) · The Prostate · doi:10.1002/pros.20071 · Cited by 19
“Several residues, including amino acid residue R273, make contact with the phosphate backbone in the major groove of the DNA helix [51].”
A mutant P53 can activate apoptosis through a mechanism distinct from those induced by wild type P53
He, M., Rennie, P. S., Dragowska, V., et al. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02609-1 · Cited by 19
Ronchetti, D., Neglia, C. B., Cesana, B. M., Carboni, N., Neri, A., Pruneri, G., & Pignataro, L. (2004) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.130.3.303 · Cited by 24
Chan, W. M., & Poon, R. Y. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3602 · Cited by 19
Germline p53 Mutation Presenting as Synchronous Tumors
Cavalier, M. E., Davis, M. M., & Croop, J. M. (2005) · Journal of Pediatric Hematology/Oncology · doi:10.1097/01.mph.0000176732.68090.c8 · Cited by 21
“Codons 273 through 286 code for the S2-S2 -H2 motif of the p53 protein, the portion that binds to the major groove of DNA.(22) Interestingly, mutations of codon 273 were not found to have a statistically significant association with ACC in Olivier s study, nor was codon 273 implicated in other report of childhood ACC.”
BackgroundFunctional analysis and molecular modeling show a preserved wild-type activity of p53C238Y
Ferrone, M. L., Perrone, F., Tamborini, E., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0012 · Cited by 19
Kong, X., Gao, H.-X., & Stanbridge, E. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103681200 · Cited by 22
Ho, W. C., Luo, C., Zhao, K., Chai, X., Fitzgerald, M. X., & Marmorstein, R. (2006) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s090744490603890x · Cited by 20
Identification of a Novel Isoform of iASPP and its Interaction with p53
Zhang, X., Diao, S., Rao, Q., Xing, H., Liu, H., Liao, X., Wang, M., & Wang, J. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.03.001 · Cited by 19
Kikukawa, M., Aoki, N., Sakamoto, Y., et al. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65170-x · Cited by 19
“All of our IHC-positive patients with mutations and monosomy 17 transformed to leukemia and were resistant to chemotherapy, which is consistent with previously reported patients.26,27 Survival of patients with a p53 mutation after the detection of monosomy 17 was significantly shorter than in patients without such a m…”
BackgroundInfluentialA fast method for predicting amino acid mutations that lead to unfolding
Wright, J. D., & Lim, C. (2001) · Protein Engineering Design and Selection · doi:10.1093/protein/14.7.479 · Cited by 19
“These mutations involve six of the most frequently mutated residues in cancer; Arg-175, Gly-245, Arg-248, Arg-249, Arg-273 and Arg-282 (Cho et al., 1994).”
BackgroundInfluentialGrunicke, H. H., Maly, K., Überall, F., et al. (1996) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(95)00015-1 · Cited by 19
Patented small molecule inhibitors of p53–MDM2 interaction
Deng, J. N., Dayam, R., & Neamati, N. (2006) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.16.2.165 · Cited by 19
“The structures of the DNA binding, tetramerisation and the C-terminal regulatory domains of human p53 have been determined by NMR or crystallography (Figures 1B and C) [26-34].”
BackgroundMethodSato, M., Kawamata, H., Harada, K., Nakashiro, K., Ikeda, Y., GOHDA, H., Yoshida, H., Nishida, T., Ono, K., Kinoshita, M., et al. (1997) · Cancer Letters · doi:10.1016/s0304-3835(96)04581-8 · Cited by 19
New p53-based anti-cancer therapeutic strategies
Wiman, K. G. (1998) · Medical Oncology · doi:10.1007/bf02787204 · Cited by 19
Siebert, A. E., Sanchez, A., Dinda, S., & Moudgil, V. K. (2011) · Systems Biology in Reproductive Medicine · doi:10.3109/19396368.2011.633152 · Cited by 19
“The transcriptional activity of p53 is determined by its ability to bind to sequence-specific DNA response elements [Cho et al. 1994; Hupp et al. 1992], and is modulated by the intranuclear concentration of the protein.”
BackgroundRegad, L., Chéron, J.-B., Triki, D., Senac, C., Flatters, D., & Camproux, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182972 · Cited by 22
Structural characterization of human RPA70N association with DNA damage response proteins
Wu, Y., Zang, N., Fu, W., & Zhou, C. (2023) · eLife · doi:10.7554/elife.81639 · Cited by 19
Novack, R., Chapman, E., Gao, J., et al. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100348 · Cited by 18
Lung specific expression of a human mutant p53 affects cell proliferation in transgenic mice
Duan, W., Gao, L., Jin, D., Otterson, G. A., & Villalona-Calero, M. A. (2007) · Transgenic Research · doi:10.1007/s11248-007-9154-3 · Cited by 18
“…Research Institute, Ohio State University, B406 Starling-Loving Hall 320 West 10th Avenue, Columbus, OH 43210-1240, USA e-mail: Miguel.villalona@osumc.edu bind to and transactivate the target genes that mediate tumor suppression (Cho et al. 1994; Ko and Prives 1996; van Oijen and Slootweg 2000).”
BackgroundMa, W., Yang, D., Gu, Y., Guo, X., Zhao, W., & Guo, Z. (2009) · Genomics · doi:10.1016/j.ygeno.2009.05.001 · Cited by 18
Regulation of ASPP2 Interaction with p53 Core Domain by an Intramolecular Autoinhibitory Mechanism
Rotem‐Bamberger, S., Katz, C., & Friedler, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058470 · Cited by 18
“The TP53 gene encoding p53 is frequently mutated in human cancers and most of these reported mutations are in the DNAbinding core domain of the protein (p53CD) [24,25].”
BackgroundStructural and functional implications of p53 missense cancer mutations
Tan, Y.-H., & Luo, R. (2009) · PMC Biophysics · doi:10.1186/1757-5036-2-5 · Cited by 19
Walerych, D., Pruszko, M., Zyla, L., Wężyk, M., Gawęda-Walerych, K., & Żylicz, M. (2018) · Oncotarget · doi:10.18632/oncotarget.25944 · Cited by 21
“…in this type of experiments the difference between FRET signals in wt and mutant p53 proteins could be caused not only by differences in protein levels, localization, activity, subcellular movement or oligomerization rate but also by known structural differences between wt and p53 mutants [40–42].”
InfluentialA molecular dynamics and docking study to screen anti-cancer compounds targeting mutated p53
Shah, H. D., Saranath, D., & Murthy, V. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1839559 · Cited by 20
Pliable DNA Conformation of Response Elements Bound to Transcription Factor p63
Chen, C., Gorlatova, N. V., & Herzberg, O. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.315820 · Cited by 21
Schaefer, K. N., & Barton, J. K. (2014) · Biochemistry · doi:10.1021/bi5003184 · Cited by 18
Hasegawa, M., Ohoka, I., Yamazaki, K., et al. (2002) · Pathology International · doi:10.1046/j.1440-1827.2002.01373.x · Cited by 18
Nuclear localization of ?-catenin in normal and carcinogenic endometrium
Nei, H., Saito, T., Yamasaki, H., Mizumoto, H., Ito, E., & Kudo, R. (1999) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199907)25:3<207::aid-mc7>3.0.co;2-4 · Cited by 95
Frequent occurrence of gastric cancer in Asian kindreds with Li–Fraumeni syndrome
Ariffin, H., Chan, A. S. L., Oh, L., Abd-Ghafar, S., Ong, G. B., Mohamed, M. B., Razali, H., Juraida, E., Teo, S., Karsa, M., et al. (2014) · Clinical Genetics · doi:10.1111/cge.12525 · Cited by 20
“There are six frequently mutated hotspots (9) with no significant difference in the distribution of mutations between the Asian and non-Asian populations (p= 0.”
BackgroundFingerman, I. M. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh625 · Cited by 18
A de novo mutation (R279C) in the P63 gene in a patient with EEC syndrome
Kosaki, R., Ohashi, H., Yoshihashi, H., et al. (2001) · Clinical Genetics · doi:10.1034/j.1399-0004.2001.600411.x · Cited by 18
“Documentation of an amino acid substitution within the DNA-binding domain in the present case, who had the EEC phenotype, further supports the notion that the location of the missense mutation within the P63 protein may be related to the phenotype.”
BackgroundInfluentialRand, A., Glenn, K. S., Alvares, C., White, M. B., Thibodeau, S. M., & Karnes, W. E. (1996) · Cancer Letters · doi:10.1016/s0304-3835(06)80030-3 · Cited by 18
Joshi, A. A., Wu, Z., Reed, R. F., & Suttle, D. P. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.2.359 · Cited by 18
“A structural change in p53 facilitates its sequence-specific binding to DNA (Cho et al., 1994) and increases expression of genes involved in cycle arrest or apoptosis.”
Background
Metadata
- Authors
- Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Science
- Published
- 1994-07-15
- Volume
- 265
- Issue
- 5170
- Pages
- 346-355
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2096276671
- Semantic Scholar
- 11096f3b08e172ce5e261795b6749818ee59c03d
- Cited by
- 2,551
- References
- 62
- Citations by year
- 2026: 62 · 2025: 52 · 2024: 40 · 2023: 64 · 2022: 61 · 2021: 73 · 2020: 67 · 2019: 62 · 2018: 61 · 2017: 54 · 2016: 64 · 2015: 62 · 2014: 81 · 2013: 78 · 2012: 68
- FWCI
- 64.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (NCI CA08748-29)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- p53 tumor suppressor, p53 core domain, DNA binding, zinc coordination, beta-sandwich, cancer genetics
- MeSH terms
- Amino Acid Sequence, Base Sequence, Binding Sites, Computer Graphics, Crystallization, DNA, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Mutation, Nucleic Acid Conformation, Protein Conformation, Genes, p53, Tumor Suppressor Protein p53, Protein Structure, Secondary, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.